Certara and Veristat Expand Clinical Trial Service Offerings
News May 15, 2013
Certara™ and Veristat, LLC. announced that they have formed an alliance to offer combined services to their clients. The joint service offering includes: Pharmacokinetic (PK) analysis, PK /Pharmacodynamic (PD) modeling, population PK modeling, trial simulation, clinical biostatistics, medical writing, data management, clinical monitoring, safety management, and project management. These combined services will help streamline the drug discovery, development and trial planning processes by improving the efficiency of data collection and analysis and enabling clients to procure value-added services through their existing vendor relationship.
“We look forward to offering Certara’s capabilities to our clients”
“We look forward to offering Certara’s capabilities to our clients,” said Patrick Flanagan, Chief Business Officer of Veristat. “Their Pharsight Consulting Services team is a world-class organization in the modeling and simulation of drugs and diseases. By combining our core services with their insight and experience, Veristat broadens our delivery platform and is able to more immediately respond to our clients’ outsourcing needs. The benefit to our clients is greater overall efficiency, impact and probability of success for their clinical trial programs.”
“We are pleased to partner with Veristat to expand what we can offer to clients as they seek to streamline their outsourcing of critical tasks in trial planning, analysis, and reporting,” said Daniel Weiner, Chief Technology Officer and head of Certara’s scientific consulting services. “Veristat specializes in several trial services that lie outside our core domain, and together we can offer more to the client than either organization could alone.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.